phosphodiesteras
pde
enzym
catalyz
hydrolysi
phosphodiest
bond
notabl
second
messeng
cascad
molecul
cyclic
adenosin
monophosph
camp
cyclic
guanosin
monophosph
cgmp
camp
cgmp
bind
regulatori
unit
protein
kinas
pka
allow
phosphoryl
thu
transduc
signal
cascad
cell
consequ
sever
cagmpdepend
pathway
pde
enorm
clinic
signific
monitor
camp
cgmp
level
cell
pde
superfamili
compris
subfamili
respect
util
differ
substrat
specif
exampl
strictli
hydrolyz
camp
hand
hydrolyz
cgmp
famili
member
target
camp
cgmp
hydrolys
mani
year
pde
enzym
remain
interest
within
pharmaceut
industri
inhibit
pde
increas
level
camp
cgmp
thu
enhanc
prolong
natur
physiolog
effect
current
variou
small
molecular
compound
discov
inhibit
pde
exampl
caffein
aminophyllin
ibmx
nonselect
pde
inhibitor
increas
intracellular
camp
therebi
activ
pka
thu
inhibit
tumor
necrosi
factor
tnf
inflammatori
cytokin
reduc
inflamm
also
select
pde
inhibitor
specif
inhibitor
inamrinon
milrinon
use
shortterm
treatment
congest
heart
failur
cilostazol
use
treatment
intermitt
claudic
inhibitor
sildenafil
tadalafil
vardenafil
boost
cgmp
level
penil
tissu
use
primarili
erectil
dysfunct
well
secondari
indic
treatment
pulmonari
hypertens
recent
opium
alkaloid
papaverin
shown
inhibit
among
pde
isoform
major
campdegrad
enzym
found
inflammatori
immun
cell
select
inhibit
prevent
releas
cytokin
inflammatori
factor
hinder
product
reactiv
oxygen
speci
lead
caus
infecti
death
us
sepsi
pneumonia
pathognomon
link
burst
cytokin
releas
ie
cytokin
storm
proinflammatori
cell
includ
macrophag
lymphocyt
polymorphonuclear
leukocyt
cytokin
storm
occur
respons
infect
virul
pathogen
host
cell
injuri
irrit
activ
multitud
receptor
immun
effector
cell
condit
exagger
hypercytokinemia
result
fatal
immun
reaction
constant
activ
immun
effector
cell
produc
sustain
supraphysiolog
level
tumor
necrosi
factor
tnf
interleukin
result
sever
tissu
injuri
often
death
thu
select
inhibit
may
amelior
cytokin
storm
prevent
tissu
injuri
earliest
pharmacopoeia
world
tang
ben
cao
complet
ad
first
known
document
forsythia
suspensa
plant
use
treat
fever
flulik
inflammatori
symptom
sinc
habitu
wide
use
asia
one
major
tradit
medicin
nowaday
extract
forsythia
suspensa
seed
use
treat
numer
inflammatori
diseas
includ
limit
erysipela
inflamm
pharyng
pyrexia
tonsil
ulcer
moreov
shown
studi
crude
extract
display
potenti
antibacteri
antivir
choleret
antipyret
effect
medicin
chemistri
studi
forsythia
seed
reveal
phenol
compound
includ
lignan
flavonol
suspect
respons
variou
biolog
activ
herb
studi
sought
better
understand
forsythia
lignan
forsythin
structurefunct
relationship
use
design
test
new
class
select
inhibitor
select
inhibitor
exert
potent
antiinflammatori
activ
sever
murin
model
inflamm
forsythin
one
major
bioactiv
compound
extract
forsythia
suspensa
seed
fig
olink
lignan
forsythin
readili
hydrolyz
remov
glucos
moieti
fig
use
structur
predict
metabolit
assess
virtual
dock
base
pymol
pdb
mkdphg
use
libdock
discoveri
studio
accelri
softwar
incbiovia
san
diego
ca
fig
e
use
zincpharm
gener
pharmacophor
model
fig
top
left
enabl
identif
high
valu
target
million
purchas
compound
librari
refin
search
perform
comput
base
dock
analysi
target
compound
use
libdock
discoveri
studio
select
compound
fig
test
use
vitro
phosphodiestereas
activ
assay
compound
fig
test
vitro
use
pdeglo
phosphodiesteras
assay
promega
madison
wi
briefli
compound
dilut
dmso
final
concentr
assay
activ
assay
mu
purifi
millipor
use
per
reaction
compound
forsythin
exhibit
custom
design
compound
exhibit
much
greater
potenc
toward
rang
nm
impress
test
compound
exhibit
select
toward
much
fig
compound
also
test
lp
stimul
fig
pbmc
fig
cell
evalu
abil
suppress
tnf
secret
compound
forsythin
exhibit
tnf
pbmc
cell
compar
custom
design
compound
exhibit
much
greater
potenc
toward
tnf
rang
nm
specif
compound
exhibit
greatest
potenc
toward
nm
fig
also
exhibit
compar
potenc
toward
tnf
rang
nm
fig
assess
vivo
antiinflammatori
activ
four
compound
mgkg
intraperiton
ip
inject
administ
lpsinduc
pneumonia
model
briefli
compound
administ
mice
variou
dose
ip
inject
min
mice
given
lp
mgkg
mice
euthan
h
later
use
pentobarbit
bal
collect
assay
tnf
cytokin
level
compound
vari
abil
amelior
lavag
cytokin
protein
concentr
total
cell
count
lpstreat
mice
fig
addit
inhibitor
diminish
histolog
evid
lung
injuri
fig
wide
use
model
sepsi
select
inhibitor
administ
mice
variou
dose
ip
inject
min
later
mice
given
lp
e
coli
ug
ip
mice
euthan
h
later
use
pentobarbit
blood
collect
assay
tnf
cytokin
level
inhibitor
exhibit
high
potenc
vivo
inhibitori
dose
tnf
mgkg
mgkg
fig
separ
experi
brief
pharmacokinet
studi
perform
inhibitor
mgkg
ip
given
mice
h
lp
administr
e
coli
ug
ip
compound
demonstr
excel
efficaci
reduc
serum
tnf
cytokin
even
h
lead
time
fig
test
compound
mice
challeng
pfumos
without
vehicl
control
treatment
ad
drink
water
contain
sucros
estim
dose
mgkgd
four
inhibitor
significantli
improv
surviv
mice
infect
compar
mice
receiv
diluent
fig
pde
inhibitor
also
decreas
lavag
cell
count
protein
concentr
lavag
cytokin
tnf
fig
impress
inhibitor
also
significantli
reduc
serum
cytokin
induc
systemat
inflamm
fig
g
test
compound
also
abl
lessen
sign
tissu
injuri
fig
result
suggest
select
inhibitor
suppress
inflamm
preserv
lung
homeostasi
pulmonari
infect
known
year
increas
camp
inhibit
gene
knockout
abl
markedli
decreas
inflammatori
respons
immun
cell
camp
control
inflamm
sever
distinct
pathway
includ
cyclic
nucleotideg
ion
channel
campactiv
protein
kinas
pka
exchang
protein
directli
activ
camp
epac
specif
camp
activ
pka
neg
regul
nfkb
pathway
thu
suppress
releas
proinflammatori
mediat
eg
moreov
camp
activ
transcript
antiinflammatori
gene
transcript
factor
creb
camp
respons
elementbind
protein
thu
pharmacolog
target
may
promis
strategi
antiinflammatori
therapi
develop
novel
class
select
inhibitor
exert
robust
antiinflammatori
activ
impair
cytokin
releas
three
preclin
model
structur
basi
drug
design
emerg
forsythin
one
major
compound
extract
forsythia
suspensa
seed
among
compound
test
studi
synthet
compound
show
potent
nm
toward
impress
compound
also
exhibit
high
select
toward
toward
pde
enzym
fig
compound
also
show
potent
nm
toward
tnf
inhibit
lp
stimul
pbmc
cell
mani
natur
compound
flavonoid
deriv
hesperetin
prunetin
also
isol
tradit
chines
medicin
select
inhibitor
rang
howev
littl
known
relationship
lignan
inhibitori
effect
protein
inflammatori
pathway
studi
determin
olink
lignan
forsythin
weak
select
inhibitor
structur
speak
compound
forsythin
highli
similar
except
forsythin
olink
vitro
forsythin
time
weaker
activ
toward
compar
compound
howev
vivo
studi
suggest
forsythin
compound
exhibit
similar
activ
sever
murin
model
fig
suggest
forsythin
may
act
prodrug
glucopyranosid
group
potenti
remov
vivo
releas
activ
lignin
common
metabol
reaction
plant
lignan
flavonol
pandem
influenza
viru
sar
viru
known
caus
danger
cytokin
storm
result
sever
damag
alveoli
lung
tissu
thu
extrem
high
mortal
rate
today
viral
pneumonia
affect
million
children
million
adult
per
year
yet
effect
treatment
support
care
murin
model
recapitul
well
deadli
human
viral
pneumonia
influenza
infect
larg
driven
exuber
host
respons
amplif
cytokin
chemokin
contribut
influenzainduc
morbid
mortal
pulmonari
viral
infect
model
complement
murin
sepsi
model
provid
assess
inhibitor
system
inflamm
endotoxin
lp
importantli
model
inflamm
inhibitor
compound
observ
lessen
sever
tissu
injuri
use
vari
mode
applic
parenter
oral
none
anim
treat
agent
exhibit
overt
sign
distress
dose
compound
also
appear
excel
vivo
mgkg
efficaci
dose
lp
pneumonia
sepsi
model
specif
compound
also
appear
long
halflif
vivo
shown
fig
septic
shock
model
carri
h
initi
treatment
mgkg
ip
yet
still
observ
decreas
serum
cytokin
overal
preclin
studi
demonstr
biolog
efficaci
select
inhibitor
murin
model
infecti
irrit
factor
trigger
cytokin
releas
select
inhibitor
could
potenti
broad
applic
acut
chronic
inflammatori
diseas
fact
select
inhibitor
roflumilast
recent
becam
first
fda
approv
inhibitor
market
roflumilast
potent
antiinflammatori
drug
particularli
pulmonari
diseas
asthma
copd
rhiniti
thu
potenti
import
drug
target
treatment
inflammatori
diseas
howev
research
develop
clearli
need
care
ascertain
safeti
profil
distribut
elimin
metabol
new
chemic
entiti
larger
model
inflamm
success
result
pharmacokinet
studi
set
stage
transit
clinic
test
subject
acut
chronic
immunerel
ill
raw
cell
atcc
pbmc
sanguin
life
scienc
activ
assay
kit
promega
mous
elisa
kit
human
r
system
lp
ecoli
sigma
forsythin
stanford
chemic
synthet
compound
purchas
chemdiv
inc
vitasm
laboratori
ltd
compound
pure
hplc
mice
euthan
use
ip
inject
mgkg
pentobarbit
approv
univers
pittsburgh
institut
anim
care
use
committe
iacuc
protocol
male
mice
purchas
jackson
laboratori
acclim
univers
pittsburgh
anim
care
facil
maintain
accord
feder
institut
anim
care
guidelin
univers
pittsburgh
institut
anim
care
use
committe
iacuc
approv
protocol
male
mice
deepli
anesthet
ketamin
mgkg
bodi
weight
intraperiton
ip
xylazin
mgkg
ip
compound
dilut
pb
variou
amount
mgkg
compound
administ
mice
though
ip
inject
min
later
mice
given
lp
e
coli
ip
inject
h
later
mice
euthan
plasma
collect
process
cytokin
assay
male
mice
purchas
jackson
laboratori
acclim
univers
pittsburgh
anim
care
facil
maintain
accord
feder
institut
anim
care
guidelin
univers
pittsburgh
institut
anim
care
use
committe
iacuc
approv
protocol
male
mice
deepli
anesthet
ketamin
mgkg
bodi
weight
intraperiton
ip
xylazin
mgkg
ip
larynx
well
visual
fiber
optic
light
sourc
endotrach
intub
plastic
cathet
compound
dilut
pb
administ
mice
mgkg
ip
inject
min
mice
given
lp
mgkg
mice
euthan
h
later
lavag
fluid
collect
mice
measur
protein
cytokin
concentr
lung
isol
mice
h
e
stain
male
mice
purchas
jackson
laboratori
acclim
univers
pittsburgh
anim
care
facil
maintain
accord
feder
institut
anim
care
guidelin
univers
pittsburgh
institut
anim
care
use
committe
iacuc
approv
protocol
male
mice
deepli
anesthet
ketamin
mgkg
bodi
weight
intraperiton
ip
xylazin
mgkg
ip
larynx
well
visual
fiber
optic
light
sourc
endotrach
intub
plastic
cathet
ul
pfumous
instil
mice
monitor
compound
treatment
stock
solut
mgml
ad
drink
water
contain
sucros
final
concentr
surviv
studi
mice
care
monitor
weight
time
mice
lost
weight
moribund
pretermin
mice
immedi
euthan
record
deceas
lavag
fluid
collect
mice
measur
protein
cytokin
concentr
lung
isol
mice
h
e
stain
dock
studi
carri
use
libdock
program
within
discoveri
studio
crystal
structur
use
dock
studi
protein
caviti
potenti
drug
bind
site
first
determin
x
z
radiu
libdock
program
paramet
number
hotspot
dock
toler
dock
prefer
high
qualiti
conform
method
fast
minim
algorithm
minim
parallel
process
true
dock
studi
top
scorerank
molecul
select
evalu
pde
activ
assay
carri
use
pdeglo
phosphodiesteras
assay
per
manufactur
instruct
promega
briefli
ul
pdeglo
reaction
buffer
contain
mu
purifi
human
recombin
millipor
ad
well
plate
test
compound
dissolv
dmso
serial
dilut
inhibitor
perform
use
pdeglo
reaction
buffer
ul
test
compound
ad
pde
enzym
final
concentr
assay
incub
room
temperatur
min
initi
pde
reaction
ul
camp
ad
reaction
mix
well
incub
room
temperatur
min
reaction
termin
use
ul
pdeglo
termin
buffer
ul
pdeglo
detect
solut
contain
pdeglo
detect
buffer
protein
kinas
ad
reaction
reaction
carri
room
temperatur
min
ul
kinaseglo
reagent
ad
reaction
mix
well
incub
minut
room
temperatur
chemic
luminesc
signal
measur
quantifi
graph
compound
test
similarli
use
mu
purifi
millipor
enzym
cell
seed
well
h
cell
prime
compound
differ
concentr
h
treat
lp
ngml
addit
h
tnf
cytokin
releas
monitor
elisa
pbmc
ml
prime
compound
differ
concentr
h
treat
lp
ngml
addit
h
tnf
cytokin
releas
monitor
elisa
tnf
secret
calcul
graph
statist
comparison
perform
prism
program
version
graphpad
softwar
inc
san
diego
ca
use
anova
unpair
ttest
p
indic
signific
